A US/UK dual citizen, Alexander (“Alex”) greatly values his strong ties on both sides of the Atlantic, following the roots of Womble Bond Dickinson. Having also spent significant portions of his childhood in Belgium and Singapore, his unique perspectives and appreciation for cultural differences emanate into his legal practice, where he is able to offer exceptional legal services that are tailored to and respect the values of clients from around the world.
Alexander is a registered patent attorney and member of the firm’s Patent Prosecution & Litigation group, with a dual focus on life sciences and biotechnology patent litigation generally, as well as pharmaceutical ANDA litigation. Alexander works closely with senior partners to provide thorough and strategic counsel to clients, utilizing the latest advancements in legal technology and artificial intelligence to provide meticulous, yet cost-efficient, work product.
Alexander received his J.D. from Vanderbilt University, where he was an editor and author for the Vanderbilt Journal of Entertainment and Technology Law. During law school, he clerked for several firms and worked in-house at a large tech insurance company, gaining experience in drafting patent opinions, utility and design patent claims and applications, reviewing possible infringement claims, and managing patent porfolios and other intellectual property matters. His experience both in-house and at private firms has provided him not only with a deep understanding of the complexities of patent law, but an understanding of the constraints and priorities of clients’ in-house attorneys.
Prior to attending law school, Alexander worked as an intern research scientist for a Fortune 500 pharmaceutical company, focusing on oncology target-validation research and CRISPR technologies. He has also presented research at annual meetings for both the Tennessee Academy of Science and the Association of Southeastern Biologists.
With a strong foundation in patent law, a global perspective, and a dedication to excellence in law, Alexander is well-positioned to continue making significant contributions to the field of life sciences patent litigation as he progressions in his career.
Thought Leadership
- "Why High Court May Have Rejected IP Obviousness Appeal," Law360, May 6, 2024
- “Why Punish Pharma for Making Medicine? Preserving Patent Protections and Cutting Consumer Costs,” 25 Vand. J. Ent. & Tech L. 603 (2023)